FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076670265> ?p ?o ?g. }

• W2076670265 endingPage "945" @default.
• W2076670265 startingPage "939" @default.
• W2076670265 abstract "Coumadin (R/S-warfarin) anticoagulant therapy poses a risk to over 50 million Americans, in part due to interpersonal variation in drug metabolism. Consequently, it is important to understand how metabolic capacity is influenced among patients. Cytochrome P450s (P450 or CYP for a specific isoform) catalyze the first major step in warfarin metabolism to generate five hydroxywarfarins for each drug enantiomer. These primary metabolites are thought to reach at least 5-fold higher levels in plasma than warfarin. We hypothesized that hydroxywarfarins inhibit the hydroxylation of warfarin by CYP2C9, thereby limiting enzymatic capacity toward S-warfarin. To test this hypothesis, we investigated the ability of all five racemic hydroxywarfarins to block CYP2C9 activity toward S-warfarin using recombinant enzyme and human liver microsomes. We initially screened for the inhibition of CYP2C9 by hydroxywarfarins using a P450-Glo assay to determine IC50 values for each hydroxywarfarin. Compared to the substrate, CYP2C9 bound its hydroxywarfarin products with less affinity but retained high affinity for 10- and 4′-hydroxywarfarins, products from CYP3A4 reactions. S-Warfarin steady-state inhibition studies with recombinant CYP2C9 and pooled human liver microsomes confirmed that hydroxywarfarin products from CYP reactions possess the capacity to competitively inhibit CYP2C9 with biologically relevant inhibition constants. Inhibition of CYP2C9 by 7-hydroxywarfarin may be significant given its abundance in human plasma, despite its weak affinity for the enzyme. 10-Hydroxywarfarin, which has been reported as the second most abundant plasma metabolite, was the most potent inhibitor of CYP2C9, displaying approximately 3-fold higher affinity than S-warfarin. These results indicate that hydroxywarfarin metabolites produced by CYP2C9 and other CYPs may limit metabolic capacity toward S-warfarin through competitive inhibition. Subsequent processing of hydroxywarfarins to secondary metabolites, such as hydroxywarfarin glucuronides, could suppress product feedback inhibition, and therefore could play an important role in the modulation of metabolic pathways governing warfarin inactivation and elimination." @default.
• W2076670265 created "2016-06-24" @default.
• W2076670265 creator A5013945168 @default.
• W2076670265 creator A5018879076 @default.
• W2076670265 creator A5027840923 @default.
• W2076670265 creator A5034219527 @default.
• W2076670265 creator A5037535034 @default.
• W2076670265 creator A5072202968 @default.
• W2076670265 date "2010-04-29" @default.
• W2076670265 modified "2023-10-18" @default.
• W2076670265 title "Hydroxywarfarin Metabolites Potently Inhibit CYP2C9 Metabolism of <i>S</i>-Warfarin" @default.
• W2076670265 cites W1712708601 @default.
• W2076670265 cites W1964046626 @default.
• W2076670265 cites W1989612908 @default.
• W2076670265 cites W1994237400 @default.
• W2076670265 cites W1999032386 @default.
• W2076670265 cites W2006931225 @default.
• W2076670265 cites W2008418425 @default.
• W2076670265 cites W2015531705 @default.
• W2076670265 cites W2022768595 @default.
• W2076670265 cites W2033735656 @default.
• W2076670265 cites W2034595467 @default.
• W2076670265 cites W2035878568 @default.
• W2076670265 cites W2037131718 @default.
• W2076670265 cites W2064601374 @default.
• W2076670265 cites W2065976317 @default.
• W2076670265 cites W2068634821 @default.
• W2076670265 cites W2075044621 @default.
• W2076670265 cites W2125791810 @default.
• W2076670265 cites W2144467912 @default.
• W2076670265 cites W2150738344 @default.
• W2076670265 cites W2156687558 @default.
• W2076670265 cites W2158049891 @default.
• W2076670265 cites W2163957072 @default.
• W2076670265 cites W2165772339 @default.
• W2076670265 cites W2166551141 @default.
• W2076670265 cites W2313892311 @default.
• W2076670265 cites W4297754350 @default.
• W2076670265 doi "https://doi.org/10.1021/tx1000283" @default.
• W2076670265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5406237" @default.
• W2076670265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20429590" @default.
• W2076670265 hasPublicationYear "2010" @default.
• W2076670265 type Work @default.
• W2076670265 sameAs 2076670265 @default.
• W2076670265 citedByCount "35" @default.
• W2076670265 countsByYear W20766702652012 @default.
• W2076670265 countsByYear W20766702652013 @default.
• W2076670265 countsByYear W20766702652014 @default.
• W2076670265 countsByYear W20766702652015 @default.
• W2076670265 countsByYear W20766702652016 @default.
• W2076670265 countsByYear W20766702652017 @default.
• W2076670265 countsByYear W20766702652018 @default.
• W2076670265 countsByYear W20766702652019 @default.
• W2076670265 countsByYear W20766702652022 @default.
• W2076670265 countsByYear W20766702652023 @default.
• W2076670265 crossrefType "journal-article" @default.
• W2076670265 hasAuthorship W2076670265A5013945168 @default.
• W2076670265 hasAuthorship W2076670265A5018879076 @default.
• W2076670265 hasAuthorship W2076670265A5027840923 @default.
• W2076670265 hasAuthorship W2076670265A5034219527 @default.
• W2076670265 hasAuthorship W2076670265A5037535034 @default.
• W2076670265 hasAuthorship W2076670265A5072202968 @default.
• W2076670265 hasBestOaLocation W20766702652 @default.
• W2076670265 hasConcept C109650736 @default.
• W2076670265 hasConcept C126322002 @default.
• W2076670265 hasConcept C181199279 @default.
• W2076670265 hasConcept C185592680 @default.
• W2076670265 hasConcept C2776301958 @default.
• W2076670265 hasConcept C2777477808 @default.
• W2076670265 hasConcept C2779161974 @default.
• W2076670265 hasConcept C3946865 @default.
• W2076670265 hasConcept C50605568 @default.
• W2076670265 hasConcept C526171541 @default.
• W2076670265 hasConcept C55493867 @default.
• W2076670265 hasConcept C62231903 @default.
• W2076670265 hasConcept C71924100 @default.
• W2076670265 hasConcept C86803240 @default.
• W2076670265 hasConcept C87644729 @default.
• W2076670265 hasConcept C98274493 @default.
• W2076670265 hasConceptScore W2076670265C109650736 @default.
• W2076670265 hasConceptScore W2076670265C126322002 @default.
• W2076670265 hasConceptScore W2076670265C181199279 @default.
• W2076670265 hasConceptScore W2076670265C185592680 @default.
• W2076670265 hasConceptScore W2076670265C2776301958 @default.
• W2076670265 hasConceptScore W2076670265C2777477808 @default.
• W2076670265 hasConceptScore W2076670265C2779161974 @default.
• W2076670265 hasConceptScore W2076670265C3946865 @default.
• W2076670265 hasConceptScore W2076670265C50605568 @default.
• W2076670265 hasConceptScore W2076670265C526171541 @default.
• W2076670265 hasConceptScore W2076670265C55493867 @default.
• W2076670265 hasConceptScore W2076670265C62231903 @default.
• W2076670265 hasConceptScore W2076670265C71924100 @default.
• W2076670265 hasConceptScore W2076670265C86803240 @default.
• W2076670265 hasConceptScore W2076670265C87644729 @default.
• W2076670265 hasConceptScore W2076670265C98274493 @default.
• W2076670265 hasIssue "5" @default.
• W2076670265 hasLocation W20766702651 @default.
• W2076670265 hasLocation W20766702652 @default.

• next